Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mifepristone for Ectopic ACTH Cushing's Syndrome
NCT00422201Phase 2Terminated
- Sponsor
- HRA Pharma
- Start
- May 2007
- Primary completion
- Apr 2012
- Modality
- Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of mifepristone in Cushing's syndrome, sponsored by HRA Pharma. Primary endpoint: Glycemic Disorders Improved or Normalized at 8 weeks. Started May 2007; status: terminated.
02
Drugs
mifepristone
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on NCT00422201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00422201.